Volume 26, Issue 1 (Iranian South Medical Journal 2023)
Iran South Med J 2023, 26(1): 1-13 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ebadi Z, Ghaffarian S. Association of WDR79 (rs2287497C>T) Poly-morphism with Breast Cancer Susceptibility in Northwest of Iran. Iran South Med J 2023; 26 (1) :1-13
URL: http://ismj.bpums.ac.ir/article-1-1771-en.html
URL: http://ismj.bpums.ac.ir/article-1-1771-en.html
1- Department of Cellular and Molecular Biology, School of Sciences, Azarbaijan Shahid Madani University, Tabriz, Iran
2- Department of Cellular and Molecular Biology, School of Sciences, Azarbaijan Shahid Madani University, Tabriz, Iran ,s.ghaffarian@azruniv.ac.ir
2- Department of Cellular and Molecular Biology, School of Sciences, Azarbaijan Shahid Madani University, Tabriz, Iran ,
Abstract: (1146 Views)
Background: The WDR79 gene encodes an antisense RNA which it is essential for stabilization and in-duction of p53 gene. WDR79 gene Single nucleotide polymorphisms are associated with cancer risk. This study was done to assess the association of WDR79 (rs2287497C>T) gene polymorphism with the risk and prognosis of breast cancer in women’s of northwest Iran.
Materials and Methods: In this case-control study, the association of WDR79 (rs2287497C>T) gene pol-ymorphism with breast cancer susceptibility was studied in a statistical population consisting of 100 pa-tients and 100 healthy controls aged 19-76 years old by Tetra ARMS-PCR. Statistical analysis was per-formed using javastat online statistics package and SPSS V.26.
Results: In the case group, the frequency of CC, TT, and TC genotypes were 76, 21, 3 percent respective-ly and they were 80, 18, and 2 percent for the control group. Also, C and T allele frequency in case group, was 86.5 and 13.5 percent and those in the control group were 89 and 11 percent respectively. Statistical analysis showed non-significant association between genotype and allele frequency and breast cancer. Also our results showed significant association between age and tumor size of patients with breast cancer in Northwestern Iran.
Conclusion: These research findings suggest that WDR79 (rs2287497C>T) polymorphism of rs2287497C/T is not related to the risk of breast cancer. There was significant relationship between this SNP polymorphism and pathological characteristic including age and tumor size.
Materials and Methods: In this case-control study, the association of WDR79 (rs2287497C>T) gene pol-ymorphism with breast cancer susceptibility was studied in a statistical population consisting of 100 pa-tients and 100 healthy controls aged 19-76 years old by Tetra ARMS-PCR. Statistical analysis was per-formed using javastat online statistics package and SPSS V.26.
Results: In the case group, the frequency of CC, TT, and TC genotypes were 76, 21, 3 percent respective-ly and they were 80, 18, and 2 percent for the control group. Also, C and T allele frequency in case group, was 86.5 and 13.5 percent and those in the control group were 89 and 11 percent respectively. Statistical analysis showed non-significant association between genotype and allele frequency and breast cancer. Also our results showed significant association between age and tumor size of patients with breast cancer in Northwestern Iran.
Conclusion: These research findings suggest that WDR79 (rs2287497C>T) polymorphism of rs2287497C/T is not related to the risk of breast cancer. There was significant relationship between this SNP polymorphism and pathological characteristic including age and tumor size.
Type of Study: Original |
Subject:
medical Genetics
Received: 2023/07/18 | Accepted: 2023/09/9 | Published: 2023/10/16
Received: 2023/07/18 | Accepted: 2023/09/9 | Published: 2023/10/16
References
1. Tvorogov D, Sundvall M, Kurppa K, et al. Somatic mutations of ErbB4: selective loss-offunction phenotype affecting signal transduction pathways in cancer. J Biol Chem 2009; 284(9): 5582-5591. [DOI]
2. Harris JR, Lippman ME, Morrow M, et al. Diseases of the breast. 5th ed. Philadelphia: Williams & Wilkins Health, 2014, 20-30.
3. Fitzmaurice C, Dicker D, Pain A, et al. The global burden of cancer 2013. JAMA Oncol 2015; 1(4): 505-527. [DOI]
4. Shamshirian A, Heydari K, Shams Z, et al. Breast cancer risk factors in Iran: a systematic review & meta-analysis. Horm Mol Biol Clin Investig 2020; 41(4): 1-16. [DOI]
5. Claus EB, Schildkraut JM, Thompson WD, et al. The genetic attributable risk of breast and ovarian cancer. Cancer 1996; 77(11): 2318-2324. [DOI]
6. Kaur RP, Vasudeva K, Kumar R, et al. Role of p53 gene in breast cancer: focus on mutation spectrum and therapeutic strategies. Curr Pharm Des 2018; 24(30): 3566-3575. [DOI]
7. Feng Y, Spezia M, Huang S, et al. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis 2018; 5(2): 77-106. [DOI]
8. Lacroix M, Toillon RA, Leclercq G. p53 and breast cancer, an update. Endocr relat Cancer 2006; 13(2): 293-325. [DOI]
9. Mahmoudi S, Henriksson S, Corcoran M, et al. Wrap53, a natural p53 antisense transcript required for p53 induction upon DNA damage. Mol Cell 2016; 64(5): 1009. [DOI]
10. Joerger AC, Fersht AR. The p53 pathway: origins, inactivation in cancer, and emerging therapeutic approaches. Annu rev biochem 2016; 85: 375-404. [DOI]
11. Pietsch EC, Humbey O, Murphy ME. Polymorphisms in the p53 pathway. Oncogene 2006; 25(11): 1602-1611. [DOI]
12. Marcello MA, Morari EC, Cunha LL, et al. P53 and expression of immunological markers may identify early stage thyroid tumors. Clin Dev Immunol 2013; 2013: 846584. [DOI]
13. Henriksson S, Rassoolzadeh H, Hedström E, et al. The scaffold protein WRAP53β orchestrates the ubiquitin response critical for DNA double-strand break repair. Genes dev 2014; 28(24): 2726-2738. [DOI]
14. Ma H, Hu Z, Zhai X, et al. Joint effects of single nucleotide polymorphisms in P53BP1 and p53 on breast cancer risk in a Chinese population. Carcinogenesis 2006; 27(4): 766-771. [DOI]
15. Hedau S, Jain N, Husain SA, et al. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India. Breast Cancer Res Treat 2004; 88(2): 177-186. [DOI]
16. Chen J, Sheng X, Ma H, et al. WDR79 mediates the proliferation of non‐small cell lung cancer cells by regulating the stability of UHRF1. J Cell Mol Med 2018; 22(5): 2856- 2864. [DOI]
17. Garcia‐Closas M, Kristensen V, Langerød A, et al. Common genetic variation in TP53 and its flanking genes, WDR79 and ATP1B2, and susceptibility to breast cancer. Int J Cancer 2007; 121(11): 2532-2538. [DOI]
18. Mędrek K, Magnowski P, Masojć B, et al. Association of common WRAP 53 variant with ovarian cancer risk in the Polish population. Mol biol rep 2013; 40(3): 2145-2147. [DOI]
19. Rao X, Huang D, Sui X, et al. Overexpression of WRAP53 is associated with development and progression of esophageal squamous cell carcinoma. PloS one 2014; 9(3): e91670. [DOI]
20. Mahmoudi S, Henriksson S, Farnebo L, et al. WRAP53 promotes cancer cell survival and is a potential target for cancer therapy. Cell death dis 2011; 2(1): e114. [DOI]
21. Hedström E, Pederiva C, Farnebo J, et al. Downregulation of the cancer susceptibility protein WRAP53β in epithelial ovarian cancer leads to defective DNA repair and poor clinical outcome. Cell death dis 2015; 6(10): e1892. [DOI]
22. Garvin S, Tiefenböck K, Farnebo L, et al. Nuclear expression of WRAP53β is associated with a positive response to radiotherapy and improved overall survival in patients with head and neck squamous cell carcinoma. Oral oncol 2015; 51(1): 24-30. [DOI]
23. Lin HY, Yang MC, Huang CH, et al. Polymorphisms of TP53 are markers of bladder cancer vulnerability and prognosis. Urol Oncol 2013; 31(7): 1231-1241. [DOI]
24. Sprague BL, Trentham-Dietz1 A, GarciaClosas M, et al. Genetic variation in TP53 and risk of breast cancer in a population-based case control study. Carcinogenesis 2007; 28(8): 1680-1686. [DOI]
25. Suguna S, Nandal DH, Kamble S, et al. Genomic DNA isolation from human whole blood samples by non enzymatic salting out method. Int J Pharm Pharm Sci 2014; 6(6): 198-199. [Article]
26. Mohamadi S, Jalali F, Rekabpour SJ. Risk Factors of Breast Cancer in Women of Bushehr City: A Case-Control Study. Iran South Med J 2023; 25(6): 505-518. (Persian) [Article]
27. Delgir S, Ilkhani K, Safi A, et al. The expression of miR-513c and miR-3163 was downregulated in tumor tissues compared with normal adjacent tissue of patients with breast cancer. BMC Med Genomics 2021; 14(1): 180. [DOI]
28. Carlson RW, Allred DC, Anderson BO, et al. Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2009; 7(2): 122-192. [DOI]
29. Darvish-Aminabad E, Sedaie-Bonab A, HosseinpourFeizi MA, et al. The Investigation of WRAP53 rs2287499 Association with Thyroid Cancer Risk and Prognosis among the Azeri Population in Northwest Iran. J Kerman Univ Med Sci 2017; 24(6): 448-458. [Article]
30. Vousden KH, Prives C. P53 and prognosis: new insights and further complexity. Cell 2005; 120(1): 7-10. [DOI]
31. Alonso S, Izagirre N, López S, et al. The diversity profile of TP53 is influenced by positive selection on the immediately upstream locus WDR79. Hum Hered 2010; 69(1): 34-44. [DOI]
32. Assad Samani L, Javadirad SM, Parsafar S, et al. TP53 rs1625895 is related to breast cancer incidence and early death in Iranian population. Indian J Clin Biochem 2019; 34(4): 485-489. [DOI]
33. Al-Eitan LN, Rababa'h DM, Alghamdi MA, et al. Correlation between candidate single nucleotide variants and several clinicopathological risk factors related to breast cancer in Jordanian women: a genotypephenotype study. J Cancer 2019; 10(19): 4647-4654. [DOI]
34. Diakite B, Kassogue Y, Dolo G, et al. p.Arg72Pro polymorphism of P53 and breast cancer risk: a meta-analysis of case control studies. BMC Med Genet 2020; 21(1): 206. [DOI]
35. Zhao L, Yin XX, Qin J, et al. Association Between the TP53 Polymorphisms and Breast Cancer Risk: An Updated Meta-Analysis. Front genet 2022; 13: 807466. [DOI]
Send email to the article author
| Rights and Permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
